Wow, might do a ph3 with "100" patients. Now where
Post# of 148294
Good to hear NASDAQ has already responded.
Wonder why EUA w/ a ph4 wasn't mentioned by Nader? That would be my preference and let the severe trial cover our ph3 needs.
Still puzzled by the fact viral load wasn't a data point recorded as was BP.